Board of directors

Born: 1953

Education/experience: Thomas Pollare holds an M.D. from Karolinska Institutet and a Ph.D. from Uppsala University. He was previously a partner in the Venture Capital company 3i. He has held VP positions at both Pharmacia Corp and Schering-Plough Inc. He has been responsible for the market approval of several pharmaceutical products in various therapeutic areas and which generated billions in annual sales. Thomas has international experience of board work in both major corporations, start-up companies, public companies and private equity investments.

Current assignments: Chairman of the Board and CEO of Oncolution AB. Chairman of the Boards of AC Intressenter AB, Sinfonia Biotherapeutics AB, AlzeCure Discovery AB and Stiftelsen AlzeCure. Member of the boards of Psilox AB and Premalux AB.

Completed assignments (past five years): Chairman of the boards of A3P Biomedical AB and BioWorks Technologies AB. Member of the boards of Pharmaceuticals Sales & Development Sweden AB, Cereno Scientific AB, Premacure Holding AB, Premacure AB, Xellia Pharmaceuticals ApS and SSI Diagnostica A/S.

Holding: 1,501,293 shares .

Dependent in relation to the company and company management, but independent in relation to the company’s largest shareholders.

Born: 1967

Education/experience: Dr Janet Hoogstraate has many years’ experience in life science, with leading roles at Astra Zeneca, among others. She has a PhD in Biopharmaceutical Sciences from the University of Leiden in the Netherlands and an eMBA from Hult International Business School. Janet has a great interest and knowledge in neuroscience research and has been, among other things, chairman of the board of the Stockholm Brain Institute. Janet is today CEO of NorthX Biologics AB, and her extensive experience in preclinical research, the pain area and biotech will be a great asset for AlzeCure.

 Current assignment: CEO of NorthX Biologics AB. Member of the board and CEO of Hoogstraate Consulting AB. Member of the board of Mireca Medicines GmbH and Apotek Produktion och Laboratorier AB. Member of the Advisory Board for Dutch Chamber of Commerce in Sweden. Member of the Portfolio Management Board for ENABLE2.

Completed assignments (past five years): Managing Director Valneva Sweden AB.

Holding: 25,000 shares.

Independent in relation to the company, company management and the company’s major shareholders

Born: 1956

Education/experience:  Eva Lilienberg holds an MSc in Pharmaceutical sciences. Eva has a broad regulatory and commercial international experience. She has also a solid experience of drug development from various senior management positions within New Products/Regulatory Affairs area at Merck, Sharp & Dohme (MSD).and have led international teams in purpose to optimize development programs to get pharmaceutical products approved, reimbursed and commercially viable. Eva has worked actively with inter alia FDA and EMA. Eva has also held various positions in AstraZeneca and HMR (now Sanofi). She has acted as Regulatory Affairs consultant in small and mid size companies. Certified Director by the Swedish Academy of Board of Directors.

Current assignments: Consultant and CEO of Kapitel Tre AB.

Completed assignments (past five years): Service Area lead/Principal Consultant for drug development project at NDA Regulatory Services AB.

Holding: 2,500 shares.

Independent in relation to the company, company management and the company’s major shareholders.

Born: 1953

Education/experience: Ragnar Linder has a Master of Science degree in Chemical Engineering from KTH Royal Institute of Technology. Ragnar is a co-founder of Pygargus, a research company in the field of realworld evidence, which was bought by IMS Health (currently IQVIA) in 2013 and in which Ragnar has held senior positions ever since. He has also held several senior positions in Amgen Nordic (CEO), Aventis, HMR and Hoechst. Ragnar has also been a member of the boards of several biotech, pharmaceutical and CRO companies. Today, Ragnar is an independent consultant.

Current assignments: Member of the board of Pharmacolog i Uppsala AB, Tegnér Biotech Consulting AB and 3D Trace AB.

Completed assignments (last five years): Member of the board of R. Linder Holding AB.

Holding: 49,698 shares.

Independent in relation to the company, company management and the company’s major shareholders.

Born: 1953

Education/experience: Professor Jan Lundberg has more than 25 years of experience from leading positions in global pharmaceutical companies, including as global head of research at Astra and then AstraZeneca (1996 – 2009) and global head of research and development at Eli Lilly (2010 – 2018). He has led the development of more than 200 drug candidates, with 30 approved products, in several therapeutic areas, including Alzheimer’s and pain. Before joining Astra, Dr. Lundberg was professor of pharmacology at the Karolinska Institute, Sweden, where he also received his PhD. He also studied medicine at the University of Gothenburg for four years and his research has resulted in over 500 publications in peer-reviewed scientific journals.

Dr. Lundberg is also an honorary doctorate at the Faculty of Pharmacology at Uppsala University, Sweden and has received both the Fernström and Jahre prizes. Over the years, he has also been active in several international authority committees. He is currently a board member of four different pharmaceutical and biotechnology companies, and his extensive experience in research and development with a strong interest in central nervous system diseases will be a great asset to AlzeCure.

Ongoing board assignments: Board member of Metabolom, Imaging analysis group, Anocca and Ferring Pharmaceuticals.

Completed board assignments (last five years): Board member of Betagenon and Ardelyx.

Holding: No shareholding.

Independent in relation to the company, company management and the company’s major shareholders